OPTCEUTICS
RESEARCH • INNOVATE • DEVELOP

Biosimilars for the intraocular use of biologics

- Bevacizumab (Avastin®) which is a monoclonal antibody used in oncology, has also been widely used for many years as an unlicensed substitute for ranibizumab (Lucentis®, an antibody Fab) to treat wet age related macular degeneration.
- Bevacizumab, and soon ranibizumab, will be off patent (as well as aflibercept, Eylea®). Several manufacturers produce bevacizumab as a biosimilar for systemic use.
- There is considerable human clinical data for the intraocular use of these the antibody based medicines.
- There is a significant opportunity to develop biosimilar and biobetter formulations of these antibody based medicines.

Use the PK-Eye™ to ensure a biosimilar is equivalent with the reference product

The PK-Eye™ replicates the human clearance times of bevacizumab which can be used as a comparison for developing a biosimilar version of bevacizumab.



Anterior profile



Cumulative clearance

Bivacizumab dose of 1.25 mg, 50 uL		
Monkey	**Human**	**The PK-Eye™**
2.4 – 3.4 days	**6.7 – 11.6 days**	**10.1 ± 0.7 days**

Email: admin@optceutics.com
Website: www.optceutics.com